Pfizer for Professionals Pfizer for Professionals




Pfizer Medical Information
(Search Medical Responses)
WyethHCP.com
(Access Wyeth for Professionals)
Explore Other Online Resources
ppn-vr-sso-links.htm
To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1-800-438-1985

Share Your Feedback
Prescribing Information
CAVERJECT IMPULSE® Dual Chamber System alprostadil for injection
Description
Return to the CAVERJECT IMPULSE Product Center

CAVERJECT contains alprostadil as the naturally occurring form of prostaglandin E1 (PGE1) and is designated chemically as (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecular weight is 354.49.

Alprostadil is a white to off-white crystalline powder with a melting point between 115° and 116°C. Its solubility at 35°C is 8000 micrograms (mcg) per 100 milliliter double distilled water.

The structural formula of alprostadil is represented below:

caverject_comp_tmb.gif

CAVERJECT IMPULSE is available as a disposable, single-dose, dual chamber syringe system. The system includes a glass cartridge which contains sterile, freeze-dried alprostadil in the front chamber and sterile bacteriostatic water for injection in the rear chamber. The alprostadil is reconstituted with the sterile bacteriostatic water just before injection. CAVERJECT IMPULSE is available in two strengths for intracavernosal administration:

10 microgram - The reconstituted solution has a volume of 0.64 mL. The delivered volume, 0.5 mL, contains 10 micrograms (mcg) of alprostadil, 324.7 mcg of alpha cyclodextrin, 45.4 mg of lactose, 23.5 mcg of sodium citrate, and 4.45 mg of benzyl alcohol.

20 microgram - The reconstituted solution has a volume of 0.64 mL. The delivered volume, 0.5 mL, contains 20 micrograms (mcg) of alprostadil, 649.3 mcg of alpha cyclodextrin, 45.4 mg of lactose, 23.5 mcg of sodium citrate, and 4.45 mg of benzyl alcohol.

When necessary, the pH of the alprostadil for injection was adjusted with hydrochloric acid and/or sodium hydroxide before lyophilization.


CAVERJECT IMPULSE Safety Information
 

Important Safety Information

CAVERJECT IMPULSE is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

The most common side effect of CAVERJECT IMPULSE was penile pain, reported by 37% of patients in clinical studies. Only 3% discontinued CAVERJECT IMPULSE for this reason.

CAVERJECT IMPULSE should not be used in men hypersensitive to alprostadil, men with conditions that may predispose them to priapism, men with anatomical deformities of the penis, men with penile implants, or men for whom sexual activity is not advisable or is contraindicated. Penile fibrosis, including Peyronie's disease, was reported in clinical trials with CAVERJECT IMPULSE.

Patients should be instructed to report any erection lasting 4 hours or longer. Treatment of priapism should not be delayed more than 6 hours.

Each patient should be titrated to the lowest effective dose.

The product information in this site is intended only for residents of the United States.

caverject_impulse_safety_information.htm
SetPProProdListVar.htm
SetPFPGroupVar.htm